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Abstract
Polyamines contribute to several physiological and pathological processes, including cardiac hypertrophy in experimental animals. This involves
an increase in ornithine decarboxylase (ODC) activity and intracellular polyamines associated with cyclic adenosine monophosphate (cAMP)
increases. The aim of the study was to establish the role of these in the human heart in living patients. For this, polyamines (by high perfor-
mance liquid chromatography) and the activity of ODC and N1-acetylpolyamine oxidases (APAO) were determined in the right atrial appendage
of 17 patients undergoing extracorporeal circulation to correlate with clinical parameters. There existed enzymatic activity associated with the
homeostasis of polyamines. Left atria size was positively associated with ODC (r = 0.661, P = 0.027) and negatively with APAO-N1-acetylsper-
mine (r = 0.769, P = 0.026), suggesting that increased levels of polyamines are associated with left atrial hemodynamic overload. Left ven-
tricular ejection fraction (LVEF) and heart rate were positively associated with spermidine (r = 0.690, P = 0.003; r = 0.590, P = 0.021) and
negatively with N1-acetylspermidine (r = 0.554, P = 0.032; r = 0.644, P = 0.018). LVEF was negatively correlated with cAMP levels
(r = 0.835, P = 0.001) and with cAMP/ODC (r = 0.794, P = 0.011), cAMP/spermidine (r = 0.813, P = 0.001) and cAMP/spermine
(r = 0.747, P = 0.003) ratios. Abnormal LVEF patients showed decreased ODC activity and spermidine, and increased N1-acetylspermidine,
and cAMP. Spermine decreased in congestive heart failure patients. The trace amine isoamylamine negatively correlated with septal wall thick-
ness (r = 0.634, P = 0.008) and was increased in cardiac heart failure. The results indicated that modifications in polyamine homeostasis
might be associated with cardiac function and remodelling. Increased cAMP might have a deleterious effect on function. Further studies should
confirm these findings and the involvement of polyamines in different stages of heart failure.
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Introduction
The polyamines putrescine, spermidine and spermine are aliphatic
molecules ubiquitously distributed in tissues that are associated
with cell replication, growth and differentiation [1, 2] and apopto-
sis [3]. Several findings demonstrate the involvement of intracel-
lular polyamines in cardiac physiology. They are associated with
metabolic [4, 5] and functional effects in rat heart preparations
in response to cardiotonic agents [6, 7]. Exogenous polyamines
produce different effects, depending on the compound assayed:
Spermine and spermidine elicit negative inotropism [8], while
putrescine produces a cardiotonic response [6, 9]. These results
might be explained by the fact that polyamines bind with differ-
ent affinities to a variety of cytoplasmic ligands [10, 11] and
many membrane proteins, including several types of ion channels
[12–14] and b-adrenoceptors, causing an increase in intracellular
cAMP [6, 15, 16].
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In experimental animals, polyamines have also been related to
several cardiac pathological conditions and diseases, such as
hypertrophy and myocardial damage in response to numerous
hormonal and trophic stimuli [17–21]. Induction of ornithine
decarboxylase (ODC), the initial enzyme in the biosynthesis of
polyamines, is known to occur in response to agents that induce
cardiac hypertrophy [22]. While overexpression of ODC in murine
hearts facilitates a severe hypertrophy in case of isoproterenol
stimulation of b-adrenoceptors [23], without alteration to the
ejection fraction [24]. The decrease in intracellular polyamines, as
a result of treatment with a-difluoromethylornithine (DFMO), an
inhibitor of ODC [25], confers protection against b-adrenergic-
mediated cardiac hypertrophy [18, 20, 26]. Therefore, a link may
exist between b-adrenoceptor stimulation and myocardial ODC
activity. On the other hand, intracellular polyamines may also
modulate b-adrenoceptor-mediated responses, as DFMO antago-
nizes isoproterenol-elicited cardiotonic effect and cAMP increases
[6, 16].
The finding of the involvement of polyamines in heart physiology
and pathology is based on in vivo and ex vivo studies in experimental
animals, and on rodent and human cultured cardiomyocytes. The lack
of human studies regarding polyamine metabolism, trace amines, and
cardiac function has led to the analysis of the correlation between bio-
chemical parameters related to the synthesis and interconversion of
intracellular polyamines and intracellular cAMP, determined in human
heart tissue samples, with clinical and echocardiographic parameters
in patients with heart failure.
Materials and methods
Patients and tissue samples
The study was carried out in 17 patients, 12 men (age 65–79 years
old) and 5 women (age 52–82 years old). Their clinical characteristics
are shown in Table 1.
A piece of right atrial appendage, 714.19  50.02 mg in weight, was
obtained at the time of atrial cannulation (in patients undergoing extra-
corporeal circulation) immediately placed at 4°C in Tyrode’s solution
(mM composition: NaCl, 137; KCl, 2.7; CaCl2, 1.8; MgCl2, 1.05;
NaH2PO4, 0.42; NaHCO3, 11.9 and glucose, 5.5), saturated with a 95%
O2 and 5% CO2 mixture, and brought to the laboratory. The elapsed
time was less than 40 min., otherwise the samples were discarded.
When the sample size allowed, it was cut into several pieces (immedi-
ately frozen in liquid nitrogen, and kept at 80°C until use) to be able
to perform as many of the proposed biochemical assays as possible on
the same right atrial appendage from a patient. The viability of the
method of preservation was studied in two patients, cutting one piece
to be frozen as soon as possible, in liquid nitrogen, and another one
after 40 min. in cold Tyrode’s solution. There were no differences
between both methods, regarding polyamines and cAMP determina-
tions, leading to preserve the samples in Tyrode solution given its
simplicity.
Human atrial samples were obtained under approval by the Regio-
nal Ethics Committee of Research, Asturias, Spain (reference 19/
2003).
Clinical parameters of the patients
The resting heart rate (beats per minute, bpm), systolic and diastolic
blood pressure (mmHg), and the presence of diseases and medications
of the patients were noted. Using 2D echocardiography the septal wall
thickness (as reference for LV hypertrophy) and the left atrial diameter,
in transversal projection, and LVEF were measured. The LVEF, septal
wall thickness and left atria size were also categorized following the
2015 Guidelines of Recommendations for Cardiac Chamber Quantifica-
tion by Echocardiography in Adults [27]. For septal wall thickness con-
siders normal a range 6–10 mm for male or 6–9 mm for female, mildly
abnormal between 11–13 mm for male or 10–12 mm for female and
moderately abnormal between 14–16 mm for male or 13–15 mm for
female. Normal left atrial size was considered as between 30–40 mm
for men and 27–38 mm for female, above these values the size is
abnormal. For the LVEF, the cut-off value of abnormal was of less than
52% for male or 54% for female [27].
For the clinical stages of heart failure the New York Heart Association
(NYHA) criteria were followed.
Measurement of cAMP in the right atrial
appendage
To measure cAMP levels, frozen samples were homogenized using a
Polytron in 1 ml of ice-cold 10 mM Tris-HCl pH 7.2 buffer containing
Table 1 Percentage of occurrence of different qualitative variables
in the patients included in the study
Variable Percentage
Sex - male/female 70.6/29.4
Cause of surgery
Coronary/valvular/both 31.3/43.8/25
CHF 68.8
NYHA - II/III 33.3/66.7
Septal wall thickness
Normal/mildly/moderately abnormal
17.6/52.9/29.4
LVEF
Normal/mildly/moderately abnormal 76.5/17.65/5.9
Arterial hypertension 76.5
Diabetes mellitus 37.5
Atrial fibrillation 25
Beta blockers 42.9
ACE Inhibitors 42.9
CCB 46.7
Smoking 46.7
ACE: angiotensin converting enzyme; CHF: cardiac heart failure; CCB:
calcium channel blockers; NYHA: New York Heart Association; LVEF:
left ventricular ejection fraction.
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4 mM ethylenediaminetetraacetic acid (EDTA). Homogenates were
boiled for 10 min. and then centrifuged at 18,000 9 g for 15 min. at
4°C. Cyclic AMP in the supernatant was measured by means of a com-
mercial radioimmunoassay kit from GE Healthcare (Little Chalfont, UK),
following the manufacturer’s instructions. Cyclic AMP levels were
expressed as pmol/mg/protein. The protein content was determined
according to the Bradford procedure.
Ornithine decarboxylase assay in the right atrial
appendage
Ornithine decarboxylase activity was determined as previously described
[7, 28]. 14CO2 released from L-[1-
14C] ornithine, substrate of the reac-
tion, was trapped in a filter paper and measured by liquid scintillation.
The specific ODC activity was expressed as pmol of 14CO2 evolved per
hour per mg of protein (pmol/hr/mg protein).
N1-acetylpolyamine oxidases assay in the right
atrial appendage
For this purpose, 100–200 mg of atrial appendage were homogenized
using a Polytron in 1 ml ice-could buffer [HEPES (2-[4-(2-hydroxyethyl)
piperazin-1-yl]ethanesulfonic acid) 10 mM, sucrose 0.25 M and EDTA
1 mM, pH 7.2] four times for 10 sec. The homogenate was centrifuged
for 10 min. at 550 9 g, at 4°C. Then, 400 ll of the supernatant were
taken and preserved at 80°C.
N1-acetylpolyamine oxidases (APAO) activity was determined by a pre-
viously described method [29]. Hydrogen peroxide, formed during the
amine oxidase reaction, was measured spectrophotometrically by cou-
pling 4-aminoantipyrine with phenol in the presence of peroxidase. N1-
acetylspermine or N1-acetylspermidine was used as substrate of the reac-
tion. Similarly, polyamine oxidase activity was assayed using spermine as
substrate instead. One unit of enzyme activity was defined as 1 nmol
H2O2 formed per min. The data were expressed as mIU/mg of protein.
Polyamine determination via high performance
liquid chromatography in the right atrial
appendage
Polyamine levels and trace amines were determined using a precolumn
derivatization method as previously described [15, 30], using dansyl
chloride. Quantification of polyamines was performed with 2-hydroxydi-
aminopropane as an internal standard. The polyamines were expressed
as nmol/mg protein.
RT-PCR analysis of RNA extracted from heart
tissues
Total RNA was isolated from the samples of the right atrial appendage
using the guanidine isothiocyanate method as previously described
[31]. RNA was twice reverse-transcribed using random hexamers as
primers and SuperScript reverse transcriptase (Invitrogen, Carlsbad,
CA, USA) following the manufacturer’s instructions. For each sample, a
negative control was prepared without transcriptase.
Target cDNAs were amplified by PCR using Taq DNA polymerase
(Biotools, Madrid, Spain) and pairs of specific primers for each gene
product, 50-TACTTCCCATCGGACTC TGG-30 and 50-CATGAGTTGCC
ACATTGACC-30 for ODC; 50-TT TGGAGAGCACCCCTTTTA-30 and 50-
TCCAAC CCTCTTCACTGGAC-30 for spermidine/spermine N1-acetyltrans-
ferase (SSAT) and 50-CAATACAGGACTC TTTCGAG-30 and 50-
TTATGGTCGGAACTAACGACG-30 for 18S rRNA, used as an internal con-
trol for relative RT-PCR.
Two reactions from each cDNA obtained were performed in a thermo-
cycler (MyCycler; Bio-Rad, Hercules, CA, USA) with an initial 4 min.
denaturation step at 95°C followed by 35 cycles of 95°C for 15 sec., 55°C
for 30 sec. and 72°C for 30 sec. in the case of ODC and SSAT and twenty
cycles for 18S rRNA. Amplified products were separated by electrophore-
sis, visualized using UV after ethidium bromide staining, and pho-
tographed using a Vilber Lourmat Photodocumentation system. The size
of the specific bands matched the predicted length of the amplicons.
Intensity of the bands was quantified using the program PhotoCaptMw
10.1 for Windows (Vilber Lourmat, Marne-la-Vallee, France).
Drugs and radiochemicals
L-[I-14C] ornithine was purchased from ICN Biomedicals (Irvine, CA,
USA). Putrescine (tetramethylenediamine), spermidine (N-[3-amino-
propyl]-1,4-butanediamine), spermine (N,N0-bis[3-aminopropyl]-1,4-bu-
tanediamine), N1-acetylputrescine (N1-Acetylputrescine hydrochloride),
N1-acetylspermidine (N1-Acetylspermidine dihydrochloride), N1-
acetylspermine (N1-Acetylspermine trihydrochloride), isoamylamine
(isopentylamine: 1-Amino-3-methylbutane) and 2-hydroxydiamino-
propane were from Sigma-Aldrich (St Louis, MO, USA). [3H]AMP
radioassay kit was from GE Healthcare (Little Chalfont, UK).
Calculations and statistical analysis
The data were expressed as the means  S.E.M. of the respective units
of measure. The statistical significance between groups was calculated
by means of Student’s t-test for unpaired data. The number of patients
was at least three in each case, otherwise the results were not taken
into account. The Pearson’s correlation coefficient (r) was used to
determine the linear relationship between two variables. Multiple regres-
sion analysis was performed to explore the relationship between the
dependent variables (left atrial size, septal wall thickness, LVEF and
heart rate) and other variables that could be used as predictors. Values
of P ≤ 0.05 were considered as significant.
Results
Clinical and biochemical parameters of the
patients
The clinical data of the patients are shown in the Table 1. The average
values of the quantitative clinical and analytical parameters were not
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separated by gender (Table 2), as statistical significance were only
observed for age, older female patients than male (73  2.64 versus
65.08  2.21 years, respectively, P = 0.046), and for putrescine and
N1-acetylspermidine determined in the right atrial appendage, which
were lower for female. These were 0.83  0.12 (n = 11) versus
0.37  0.11 (n = 5) nmol/mg protein (P = 0.017) for putrescine and
34.04  5.95 (n = 10) versus 11.29  2.82 (n = 4) nmol/mg pro-
tein (P = 0.004) for N1-acetylspermidine respectively for male versus
female.
Principal component analysis and correlations of
polyamines and the enzymes of synthesis and
homeostasis and/or cAMP determined in the
right atrial appendage
Ornithine decarboxylase activity and endogenous polyamines, deter-
mined in the right atrial appendage, were subjected to principal com-
ponent analysis. The correlation matrix showed the presence of many
coefficients of 0.3 and above. The Kaiser–Meyer–Olkin value was
0.64, exceeding the recommended value of 0.6 [32] and Bartlett’s
Test of Sphericity [33] reached statistical significance (P = 0.027),
supporting the factorability of the correlation matrix.
Principal component analysis revealed a two-component solution
explained a total of 82.35% of the variance, with component 1 con-
tributing 57.63% and component 2 24.72% respectively. The Oblimin
rotation solution revealed the presence of simple structure [34], with
both components showing a number of strong loadings. There was a
weak positive correlation between the two factors (r = 0.211)
(Table 3).
The linear regression analysis of the biochemical determination
showed that ODC activity of the right atrial appendage positively and
significantly correlated with the determinations of the polyamines
spermidine (r = 0.585, P = 0.046, n = 12) and spermine (r = 0.675,
P = 0.023, n = 11) (Fig. 1A), but not to putrescine (r = 0.405,
P = 0.217, n = 11). There existed a positive correlation between the
determinations of N1-acetylspermidine and putrescine (r = 0.747, P =
0.003, n = 14) (Fig. 1B), putrescine and N1-acetylputrescine (r =
0.542, P = 0.045, n = 14) (Fig. 1C) and between spermidine and sper-
mine (r = 0.773, P = 0.001, n = 15).
Ornithine decarboxylase and APAO-N1-acetylspermidine activity
tended towards a negative correlation, although it was not statistically
significant (r = 0.617, P = 0.103, n = 8), and APAO-N1-acetylsper-
midine correlated negatively with spermine (r = 0.779, P = 0.023,
n = 8).
Cyclic AMP, assayed in the right atrial appendage, negatively and
significant correlated with ODC activity (r = 0.885, P = 0.004,
n = 8) (Fig. 1D) and spermidine (r = 0.735, P = 0.010, n = 11),
and without statistical significance with spermine (r = 0.574,
P = 0.065, n = 11) (Fig. 1E).
Left atria size and septal wall thickness
association with polyamines and the enzymes of
synthesis and homeostasis determined in the
right atrial appendage
Left atrial size significantly correlated with ODC (r = 0.661,
P = 0.027, n = 11) (Fig. 2A) and APAO-N1-acetylspermine
(r = 0.769, P = 0.026, n = 8) (Fig. 2B) activity, and with the ODC/
APAO-N1-acetylspermidine ratio (r = 0.680, P = 0.044, n = 9)
Septal wall thickness ranged from 9 to 14 mm, 3 (23.5%) patients
having a normal range, 9 (47.1%) mildly abnormal and 5 (29.4%)
Table 2 Mean values  S.E.M. of clinical variables of the patients
and biochemical determinations in the right atrial appendage, the
number of data in each case is indicated in brackets
Variable
Value
(mean  S.E.M.)
Age (17) years (male/female) 65.08  2.21
73  2.64
Heart rate (16) beats per minute 80.86  2.67
Systolic blood pressure (16) mmHg 141.33  3.91
Diastolic blood pressure (16) mmHg 77.33  3.3
Ventricular septal thickness (17) mm 12.06  0.38
Left atria size (14) mm 42.79  3.54
LVEF (17) percentage 55.49  1.71
cAMP (12) pmol/mg protein 12.37  1.77
ODC (13) pmol/hr/mg protein 14.67  2.51
Putrescine (16) nmol/mg protein 0.64  0.11
Spermidine (16) nmol/mg protein 1.08  0.09
Spermine (16) nmol/mg protein 2.7  0.21
N1-Acetylputrescine (15)
nmol/mg protein
0.38  0.02
N1-Acetylspermidine (14)
nmol/mg protein
28.35  5.47
SMO (9) mIU/mg protein 0.30  0.04
APAO-N1-Acetylspermidine (8)
mIU/mg protein
0.09  0.01
APAO-N1-Acetylspermine (9)
mIU/mg protein
0.13  0.02
Isoamylamine (16) nmol/mg protein 0.48  0.14
APAO: acetyl polyamine oxidase; cAMP: cyclic adenosine monophos-
phate; LVEF: left ventricular ejection fraction; ODC: ornithine decar-
boxylase; SMO: spermine oxidase; IU: international units; SEM:
standard error of the mean.
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moderately abnormal (Table 1). The patients having LV hypertrophy
were significantly older, 69.14  2.07 years, than those without
hypertrophy, 59.33  0.67 years (P < 0.001). They also had a sig-
nificant increase in the heart rate by comparison to the patients with
normal septal thickness, 82  3.06 versus 72  2.08 bpm
(P = 0.022).
Table 3 Pattern and Structure Matrix for principal components analysis with Oblimin Rotation of Two Factor Solution of ornithine
decarboxylase (ODC) activity and endogenous polyamines determined in the right atria appendage
Pattern matrix Structure matrix
Communalities
Component 1 Component 2 Component 1 Component 2
Spermine 0.960 0.940 0.892
Spermidine 0.935 0.893 0.836
ODC 0.681 0.394 0.764 0.538 0.732
N1-Acetylputrescine 0.578 0.515 0.687 0.637 0.725
Putrescine 0.984 0.958 0.933
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Septal wall thickness was negatively correlated with isoamylamine
(r = 0.634, P = 0.008, n = 16) (Fig. 2C), and the one-way ANOVA
showed significant differences (P < 0.001) when the variable was
categorized (normal: 9.33  0.33 mm, n = 3; mildly abnormal:
12.11  0.2 mm, n = 9; moderately abnormal: 13.6  0.24 mm,
n = 5). Correlations with other variables were not observed.
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The multivariable regression analysis did not find indepen-
dent variables as predictors of left atria size or septal wall thick-
ness.
Patient cardiac functional parameters and its
correlation with polyamines and homeostasis
and/or cAMP in right atrial appendage
Of the 17 patients, 12 were diagnosed of congestive heart failure.
These patients showed a significant increase in the left atrial size with
respect to those without it (Fig. 3A). Congestive heart failure was also
associated with a significant decrease in spermine levels (Fig. 3B)
and an increase in isoamylamine (Fig. 3C) in the right atrial appen-
dage.
The functional implication of polyamines on heart function
was studied by the analysis of the linear correlation of the
different variables with the LVEF. Spermidine (r = 0.690,
P = 0.003, n = 16) was positively and significantly correlated
with the LVEF (Fig. 4A), as well as spermine, although without
statistical significance (r = 0.488, P = 0.065, n = 16), and negative
for N1-acetylspermidine (r = 0.554, P = 0.032, n = 15)
(Fig. 4B) and APAO-N1-acetylspermidine (r = 0.701, P = 0.035,
n = 9).
Patients that did not have preserved ejection fraction showed a
significant decrease in ODC activity in atrial appendage (8.42  1.95,
n = 3 versus 16.55  1.75, n = 10, P = 0.03) and almost a signifi-
cant decrease in the ODC/cAMP ratio (0.52  0.3, n = 3 versus
2.16  0.41, n = 7, P = 0.069) with respect to a normal LVEF.
Spermidine (r = 0.590, P = 0.021, n = 15) was positively and
significantly correlated with the heart rate of patients (Fig. 4A) and
negatively with N1-acetylspermidine (r = 0.644, P = 0.018,
n = 13) (Fig. 4B). The LVEF and heart rate were positively and signifi-
cantly correlated between each other (r = 0.675, P = 0.006, n = 15).
Left ventricular ejection fraction negatively and significantly corre-
lated with cAMP (r = 0.850, P = 0.001, n = 13) and almost for
heart rate (r = 0.610, P = 0.061, n = 10) (Fig. 4C). As well as
LVEF with the cAMP/ODC (r = 0.794, P = 0.011, n = 10), cAMP/
spermidine (r = 0.813, P = 0.001, n = 13) and cAMP/spermine
(r = 0.747, P = 0.003, n = 13) ratios.
The multivariable regression analysis did not find independent
variables as predictors of LVEF. However, spermidine, spermine and
N1-acetylspermine explained 75.8% of the variance in heart rate
(P = 0.008). These independent variables also made a statistical sig-
nificant unique contribution to heart rate. The equation of the model
was: Yheart rate = 91.03 (constant) + spermidine 9 19.83+ sper-
mine 9 9.06+ N1-acetylspermine 9 0.32.
Patients treated with atenolol showed a decrease in the LVEF
52.67  2.78% (n = 6) in comparison with untreated patients of
60  1.32% (n = 8), P = 0.024. No significant differences were
observed in the remaining variables analysed, except on age
62.5  2.59 (n = 6) for treated patients by comparison with
untreated of 70.50  2.31% (n = 8), P = 0.04.
No significant differences were observed in the variables analysed
regarding the NYHA stages II and III, or whether the patients had a
coronary or valvular disease.
Determination of ODC and SSAT gene expression
levels in right atrial appendage
RT-PCR experiments were carried out to determine the ODC and
SSAT mRNA profile. This showed that ODC and SSAT expression was
similar in the 12 patients from whom tissue availability allowed the
performance of RT-PCR (Table 4; Fig. 5).
Discussion
The results showed for the first time in humans that the polyamine
pathway and trace amines, analysed in right atrial appendage, are
associated with clinical and/or echocardiographic parameters of
patients presenting heart failure, with regard to the effects on cardiac
remodelling and function. The findings are relevant as they were
obtained in heart samples taken from living patients to compare with
diverse studies of cardiac hypertrophy induced in animal models,
where ODC activity and polyamines play an important role in cardiac
function and remodelling.
Most patients in the study had heart failure, two-thirds were male
and, as expected, females were older than male [35]. The absence of
values of polyamines or the activity of the enzymes related to their
synthesis and interconversion in heart samples of healthy individuals
(unlikely candidates for cardiac surgery with extracorporeal circula-
tion) led us to analyse the correlation between the biochemical deter-
Table 4 Sex, age and clinical and biochemical parameters of the patients included in Figure 5
Patient Sex Age (years) LAS (mm) SWT (mm) LVEF (%) CHF NYHA ODC (pmol/hr/mg protein)
RAA-1 Male 69 49 13 43 Yes II 4.25
RAA-2 Female 69 45 12 60 No II 7.73
RAA-3 Female 60 50 9 52 Yes III 23.4
RAA-4 Male 78 55 14 60 Yes III 27
RAA: right atrial appendage; CHF: cardiac heart failure; LAS: left atria size; LVEF: left ventricular ejection fraction; LVH: left ventricular hypertro-
phy; NYHA: New York Heart Association; ODC: ornithine decarboxylase; SWT: septal wall thickness.
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minations in the right atrial appendage with respect to clinical param-
eters of the patients.
The results of the biochemical analysis showed that the polyamine
pathway is present in human heart samples of the right atrial appen-
dage (Fig. 6).
They fitted, using factorial analysis, into two components, reflect-
ing an interrelationship, with biological meaning, in a subset of the
total variables studied. There is a first component for spermine, sper-
midine, ODC and N1-acetylputrescine, and a second for ODC, N1-
acetylputrescine and putrescine. Moreover, there existed a linear cor-
relation between polyamines and certain enzymes of the synthesis
and catabolism of polyamines. Thus, this was positive and significant
between ODC activity (which converts ornithine into putrescine) [36]
and the levels of spermidine and spermine. Although no correlation
was observed for putrescine. This could be related to the short half-
life of putrescine, converted to spermidine (by spermidine synthase)
and N1-acetylputrescine (via N-acetyltransferase) [37], with which it
is positively correlated. Putrescine may also be excreted [38], making
the correlation with a specific enzyme or polyamine difficult. In the
atrial appendage of these patients spermine oxidase could play a
minor role in the catabolism of spermine.
In the patients studied, ODC activity and intracellular polyamines
were associated with trophic and functional parameters (Fig. 6). In
this sense, left atrial size was positively associated with a positive
anabolic/catabolic ratio of polyamines, as shown by its positive corre-
lation with ODC/APAO-N1-acetylspermidine activity ratio. These
changes might be related to a causal effect and/or as a response to
the left atrial dilation.
Left atrial size is clinically related to a sustained overload; in fact
the patients with cardiac heart failure have increased left atrial size.
This may be a consequence of diastolic (because of ventricular hyper-
trophy) and/or systolic dysfunction. With regard to diastolic dysfunc-
tion, a correlation with septal wall thickness should be expected, but
this was not the case, ruling out such a possibility in these patients.
Activation of polyamine metabolism, by induction of ODC, has
been proposed as an adaptive mechanism of heart through cardiac
hypertrophy [39], being also associated with ventricular systolic
dysfunction [24]. However, our results showed that septal wall thick-
ness was not correlated with ODC and APAO-N1-acetylspermidine
activity, increased polyamine levels or changes in the expression of
ODC and SSAT. This suggests that, at least, in mild to moderately
abnormal septal wall thickness the association of polyamines with
cardiac deleterious effect reported in experimental animals were not
observed. We cannot rule out an anabolic effect of polyamines in car-
diac hypertrophy in the case of severely abnormal thickness, because
none of the patients fulfilled this criterion.
Left atrial overload might be a compensatory signal for increasing
the synthesis/catabolism ratio of polyamines preventing systolic dys-
function in these patients. In this sense, intracellular levels of sper-
midine were positively correlated with LVEF and resting heart rate.
Consistent with this finding, the catabolism of spermidine, taking into
account the increase in N1-acetylspermidine, was negatively associ-
ated with LVEF and resting heart rate. The resting heart rate could be
predicted in 3/4 of patients via the values of spermidine, spermine
and N1-acetylspermidine determined in the right atrial appendage.
In patients with an abnormal LVEF ODC activity and its ratio with
cAMP were significantly decreased by comparison with those having
preserved function. When they had congestive heart failure a signifi-
cant decrease in the intracellular levels of spermine in the right atrial
appendage was observed. Overall, intracellular polyamines seem to
be important for cardiac function. Similarly, the up-regulation of
polyamines synthesis contributes to preconditioning-induced cardio-
protection and attenuation of contractile dysfunction in the murine
heart [40, 41].
The cellular effects of polyamines are complex. Thus, polyamines
function as reactive oxygen species (ROS) scavengers and anti-in-
flammatory molecules [42–44]. But increased intracellular levels of
polyamines are cytotoxic, being this effect prevented by the catabolic
ODC
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2
RA
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3
RA
A-
4
SSAT
Fig. 5 Levels of mRNA corresponding to ornithine decarboxylase (ODC)
and spermidine/spermine N1-acetyltransferase (SSAT) measured by RT-
PCR in human right atrial appendage; 18S rRNA was used as an inter-
nal control for relative RT-PCR, corresponding to the patients of
Table 4. RAA: atrial appendage.
N1-acetylputrescine
N-AT
Uptake
Export
Spermine
synthase
cAMP
LVEF
HR
LVEF
HR
N1-acetylspermidine
ODC
APAO
CO2
LAS
N1-acetylspermine
APAO
SSAT
SSAT
SMO
LAS
L-Ornithine
Putrescine
Spermidine
Spermine
Fig. 6 Relationship of polyamine metabolism with biochemical, func-
tional and morphological parameters in the heart. The lines show the
correlations between polyamines, enzymatic activities and cAMP with
the left atrial size (LAS), the left ventricular ejection fraction (LVEF) and
the heart rate (HR). (+) and solid lines positive correlation; () and dot-
ted lines negative correlation. APAO: N1-acetypolyamine oxidase; N-AT:
N1-acetyltransferase; ODC: Ornithine decarboxylase; SMO: Spermine oxi-
dase; SSAT: Spermidine/spermine N-acetyltransferase.
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enzymes [45, 46]. However, the oxidation reactions, via APAO, may
also lead to the formation of ROS [36], which are associated with
contractile dysfunction [47, 48]. Arginase may also be involved in
polyamine metabolism and ROS formation contributing to myocardial
injury during ischemia-reperfusion [49]. Reactive oxygen species
may transduce b-adrenoceptor signalling and activate protein Kinase
A (PKA), even independently of b-adrenergic stimulation and cAMP
concentration [48]. Polyamines and b-adrenoceptor system are func-
tionally connected in experimental models [6, 16, 18, 21, 23].
In the right atrial appendage of the patients studied, cAMP was
negatively associated with ODC activity, spermidine and spermine
levels. Cyclic adenosine monophosphate and the cAMP/ODC, cAMP/
spermidine and cAMP/spermine ratios are negatively associated with
LVEF. However, cAMP levels were not related to left atrial size and
ventricular septal thickness. This underlines the possibility of contrac-
tile dysfunction when cAMP increases, and that higher ODC activity
and intracellular spermidine and spermine levels could improve it. An
inverse association between intracellular polyamines and cAMP was
also reported in primary beating heart cells of chick embryos [50]. In
any case, intracellular cAMP accumulation might be determinant,
among other mechanisms [51–53], in adverse cardiac remodelling
and deleterious function [54, 55].
It is interesting that some patients included in the study were trea-
ted with atenolol, a cardioselective b-blocker, which should prevent
the increase in intracellular cAMP, but this was not the case. This
indicates that in these patients, cAMP levels might be independent of
b1-adrenoceptor stimulation. Heart failure, initially compensated for
by sympathetic activation of b-adrenoceptors, turned into a dimin-
ished inotropic reserve of the heart, because of an altered expression
of the b1/b2-adrenoceptors ratio, its coupling to G-proteins and phos-
phodiesterases [56–58], and cAMP compartmentalization, leading to
cardiotoxic signalling [59–61]. Furthermore, cAMP may activate PKA
eliciting contractile dysfunction and hypertrophy of the heart [47].
Besides polyamines, isoamylamine, a primary amine produced by
leucine decarboxylation, was present in the right atrial appendage.
This is characterized as agonists of trace amine-associated receptors
[62], but in the heart its source and function are not known. Isoamy-
lamine negatively correlated with septal wall thickness and was
increased in the patients with cardiac heart failure. According to
these findings, it might be used as potential marker of cardiac dis-
eases.
According to these results, ODC activity is associated with left
atrial hemodynamic overload and polyamines with an improvement in
ventricular inotropism, which might be a compensatory mechanism
to preserve cardiac contractility. These associations do not necessary
imply a causal relationship with cardiac pathology, or that the bio-
chemical changes observed in the polyamine pathway in the right
atrial appendage occur in the left ventricles or whether they play a role
in the physiopathology of cardiac diseases. Although they can also be
released from cells and produce biological effects in cardiomyocytes
[63]. In any case, at least the polyamines and isoamylamine may be
potential markers. Further studies should establish their role in the
transition from compensatory hypertrophy to dysfunction.
In addition, the pharmacological treatment of cardiac hypertrophy,
as well as cancer chemotherapies, based on the inhibition of ODC and
a decrease in intracellular polyamines, must be carefully considered
in terms of cardiac function.
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